DataMEDS AI MEDS 深 沪
等待开盘 10-19 09:30:00 美东时间
2.63
-0.220
-7.72%
华盛通- 最 高2.86
- 今 开2.80
- 成交量 30.94万股
- 最 低 2.6201
- 昨 收 2.85
- 总市值 840.98万
- 52周最高 2228.00
- 市盈率 静 --
- 换手率 9.68%
- 52周最低 0.8225
- 委 比 57.54%
- 总股本 319.76万
- 历史最高 2228.00
- 量 比 0.07
- 振 幅 8.42%
- 历史最低 0.8225
- 每 手 1
- 风险率 1.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Datameds AI Subsidiary Helomics Receives Medicaid Coverage Determination In Gynecologic Cancers For The ChemoFx Assay In Gynecologic Cancers
DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company vertically integrating its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced t...
10-12 18:04
Reported Earlier: DataMeds AI, Tollo Health Roll Out Health Lives Here Mobile Application
DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, and Tollo Health, LLC ("Tollo"), a heal...
09-29 00:02
DataMeds AI Stock Surges on Mobile App Launch
DataMeds AI Inc. (NASDAQ:MEDS) shares are surging Monday morning following the launch of its "Health Lives Here" mobile application, a joint initiative with Tollo Health and the NFL Alumni Association. Here’s what investors need to know. DataMEDS AI shares are powering higher. Why are MEDS shares ra...
09-28 22:59
DataMeds AI Settles Litigation, Strengthens Balance Sheet
DataMeds AI ( ($MEDS) ) has issued an announcement. On September 11, 2026, Data...
09-18 06:02
DataMEDS AI shares are trading higher after Axe Compute announced the sale of its legacy AI cancer diagnostics laboratory business, Helomics, to DataMEDS in an all‑stock transaction.
DataMEDS AI shares are trading higher after Axe Compute announced the sale of its legacy AI cancer diagnostics laboratory business, Helomics, to DataMEDS in an all‑stock transaction.
09-16 00:44
DataMEDS AI reports Q2 results
DataMEDS AI press release (MEDS): Q2 Net loss per share was $7.13 Revenue was $1.779M in Q2 2026, up 14% sequentially from Q1 2026 and above management projections. More on Wellgistics Health Wellgist...
08-19 15:33
DataMEDS AI Q2 EPS $(7.13) Down From $(5.40) YoY, Sales $1.780M Down From $7.791M YoY
DataMEDS AI (NASDAQ:MEDS) reported quarterly losses of $(7.13) per share. This is a 32.04 percent decrease over losses of $(5.40) per share from the same period last year. The company reported $1.780 million in sales this quarter. This is a 77.15 percent decrease over sales of $7.791 million the sam...
08-17 21:05
DataMeds AI Reports Pharmacy Unit Corexa Health July Sales Of $600K+ With Annual Run Rate $7M+; Corexa Completes Registration With TrumpRx To Offer Patients Access To Oral GLP-1 Agonist Drugs
DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), an integrated healthcare company leveraging its Health IT infrastructure and artificial intelligence platform EinsteinRx™ combined with blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solu...
08-12 19:44
Wellgistics Health Signs Transformative Strategic Acquisition Agreement
An announcement from Wellgistics Health Inc ( ($WGRX) ) is now available. On Ju...
08-05 05:38
DataMeds AI, Datavault AI Amend Definitive Agreement To Expand PharmacyChain Blockchain-Related Technology Licensing Relationship Beyond Pharmaceutical Distribution
DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMEDS"), a Health IT company leveraging its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contacts platform PharmacyChain™ to provide integrated solutions for the generation, rationalization, intervention, transaction and monetization ...
07-29 22:17
